Full-Time

Senior Clinical Trial Manager

Clinical Operations, Oncology Trials

Posted on 9/28/2025

Adicet Bio

Adicet Bio

51-200 employees

Off-the-shelf gamma delta T therapies

Compensation Overview

$161k - $223k/yr

+ Annual cash bonus + Long-term incentives (equity) + Employee Stock Purchase Plan (ESPP) + 401(k) with Roth + Company match 4.5%

San Carlos, CA, USA

Hybrid

Onsite required at least three days per week (Tuesday–Thursday).

Category
Business & Strategy (7)
, , , , , ,
Required Skills
Word/Pages/Docs
Google Cloud Platform
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • BS or higher degree in science, nursing (RN or BSN), or equivalent discipline
  • A minimum of 6 years of clinical research experience in biotechnology, pharmaceutical, or CRO industry
  • Experience supporting studies in a fast-paced environment
  • Success in working with CROs and vendors
  • Excellent communication skills and ability to achieve milestones in a team environment
  • Strong working knowledge of FDA, ICH Guidelines, and GCPs governing the conduct of clinical trials
  • Proficiency with Microsoft Word, Excel, PowerPoint and Project
  • Onsite requirement: employees are required to be onsite at least three days per week (Tuesday–Thursday mandatory), with some roles requiring full-time onsite presence
Responsibilities
  • Ensure clinical trial activities and deliverables are completed on-time, within budget, and in a complex environment in accordance with quality and GCP standards with minimal oversight
  • Lead the identification, evaluation, selection, and oversight of clinical trial sites, vendors and CROs
  • Work closely with the Clinical Operations team to support all aspects of clinical studies
  • Manage multiple clinical study vendors with oversight of activities.
  • Plan and conduct Investigator’s meetings
  • Take a leadership role in certain site and study management activities including: ICFs, site activations, monitoring reports and study plans
  • Collaborate with cross functional team members to independently address routine study issues
  • Assist with CRO and/or vendor oversight and management to ensure milestones are achieved
  • Identify issues for escalation, participate in problem solving and implementation of risk mitigation
  • Participate in departmental and corporate initiatives
  • Perform co-monitoring visits with CRO, on an as needed basis, to provide oversight during site qualification, site initiation, routine monitoring, and close-out visits
  • Ensuring data entry is up to date and site queries are resolved in a timely manner
  • Assist with department compliance initiatives and SOP writing
  • Generate and maintain reports, study trackers, internal and external presentations and study documents as needed
  • Ensure close tracking of site enrollment and related metrics
  • Establish and manage clinical trial master files (TMF).
  • Complete other responsibilities as assigned

Adicet Bio develops cancer immunotherapies using donor-derived, allogeneic gamma delta T cells that are engineered to target and kill cancer cells. The therapy uses off-the-shelf cells instead of a patient’s own cells, making treatment faster and potentially more readily available. The product works by introducing these modified T cells into a patient, where they seek out and destroy tumor cells. Adicet Bio differentiates itself by providing an immediately available, genetically modified immune cell therapy rather than patient-specific treatments, and by focusing on gamma delta T cells, which may offer targeted anti-tumor activity with a different safety and efficacy profile. The company aims to bring these therapies to patients through commercialization, licensing, and partnerships with healthcare providers and larger pharma companies, supported by ongoing research and development and strategic initiatives like the merger with resTORbio and a substantial funding round.

Company Size

51-200

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Prula-cel Phase 1 enrolls over 20 autoimmune patients across seven cohorts by December 2025.
  • FDA aligns outpatient dosing for prula-cel in lupus nephritis and SLE patients.
  • $75M October 2025 raise extends cash runway into second half of 2027.

What critics are saying

  • Allogene's ALLO-316 superior Phase 1 data erodes ADI-270 competitiveness in 6-12 months.
  • GammaDelta Therapeutics' 40% ORR γδ1 CAR-T enters Phase 1/2 for CD70+ lymphomas in 12-18 months.
  • Cash burn hits $25M/quarter, forcing dilutive financing before 2027 at sub-$1/share.

What makes Adicet Bio unique

  • Adicet engineers gamma delta T cells with CARs and TCR-like antibodies for selective tumor targeting.
  • ADI-270 features dual anti-tumor mechanisms overcoming CD70-low tumor heterogeneity.
  • ADI-212 includes dominant-negative TGFβ receptor armoring against suppressive TME.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Adicet Bio who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Paid Vacation

Paid Sick Leave

Paid Holidays

Parental Leave

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

2%

2 year growth

1%
TipRanks
Jan 7th, 2026
Adicet Bio doubles prula-cel Phase 1 enrolment, extends cash runway to 2027 with $75M raise

Adicet Bio has expanded enrollment in its Phase 1 prula-cel programme for autoimmune diseases to over 20 patients as of 31 December 2025, more than doubling since October. All seven autoimmune cohorts are now actively enrolling, including the first ANCA-associated vasculitis patient. The company has secured FDA alignment for outpatient dosing of lupus nephritis and systemic lupus erythematosus patients. Adicet is also advancing ADI-212 for metastatic castration-resistant prostate cancer, targeting a regulatory filing in the first half of 2026. An October 2025 equity raise of approximately $74.8 million has extended the company's cash runway into the second half of 2027. Multiple clinical data updates are planned throughout 2026 as Adicet works towards a pivotal trial design.

Investing.com
Oct 7th, 2025
Adicet Bio $80M Stock Offering Announced

Adicet Bio (NASDAQ:ACET) announced an $80 million stock offering, pricing 70,001,000 shares at $1 each and pre-funded warrants for 10 million shares at $0.9999. The offering, expected to close by October 8, 2025, aims to bolster finances amid rapid cash burn. Jefferies and Guggenheim Securities are joint book-running managers. Adicet also reported positive results from its ADI-001 trial and halted ADI-270 development, reducing its workforce by 30% to extend cash reserves into Q4 2026.

BioProcess International
Aug 13th, 2025
Auspicious alliance: MaxCyte and Adicet partner to develop off-the-shelf T-cell therapies

Auspicious alliance: MaxCyte and Adicet partner to develop off-the-shelf T-cell therapies.

Stock Titan
Aug 4th, 2025
MaxCyte Signs Platform License Agreement with Adicet Bio

MaxCyte (NASDAQ:MXCT) has signed a strategic platform license agreement with Adicet Bio for the use of MaxCyte's Flow Electroporation(R) technology and ExPERT(TM) platform.

Ochre Digi Media Pvt Ltd.
Feb 28th, 2025
Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Systemic Sclerosis Treatment

Adicet Bio receives FDA Fast Track Designation for ADI-001 in systemic sclerosis treatment.

INACTIVE